Volume 81, Issue 1
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645


isolates from French Guiana were studied for the presence of mutations associated with sulfadoxine/pyrimethamine (SP) drug resistance. Ninety-six blood samples were collected from 2000 to 2005 from symptomatic malaria patients. SP drug resistance was predicted by determining point mutations in the dihydrofolate reductase () and dihydropteroate synthase () genes. All samples showed mutant genotypes in both genes with a prevalence > 90% for the 58R, 117N, 382C, and 383G. A new mutation (116G) in was found at a frequency of 3.3%. Six different multilocus genotypes were observed with the predominance of the quintuple mutant-type 58R/117N/173L–382C/383G (59.3%). No significant differences were observed between the prevalence of haplotypes and the year of collection. Our results indicate that, in this area, the fixation of SP drug-resistant parasites in the population is stable.


Article metrics loading...

The graphs shown below represent data from March 2017
Loading full text...

Full text loading...



  1. Mendis K, Sina BJ, Marchesini P, Carter R, 2001. The neglected burden of Plasmodium vivax malaria. Am J Trop Med Hyg 64 : 97–106. [Google Scholar]
  2. Hay SI, Guerra CA, Tatem AJ, Noor AM, Snow RW, 2004. The global distribution and population at risk of malaria: past, present, and future. Lancet Infect Dis 4 : 327–336. [Google Scholar]
  3. Price RN, Tjitra E, Guerra CA, Yeung S, White NJ, Anstey NM, 2007. Vivax malaria: neglected and not benign. Am J Trop Med Hyg 77 : 79–87. [Google Scholar]
  4. Duarte EC, Gyorkos TW, Pang L, Abrahamowicz M, 2004. Epidemiology of malaria in a hypoendemic Brazilian Amazon migrant population: a cohort study. Am J Trop Med Hyg 70 : 229–237. [Google Scholar]
  5. Legrand E, Volney B, Meynard JB, Mercereau-Puijalon O, Esterre P, 2008. In vitro monitoring of Plasmodium falciparum drug resistance in French Guiana: a synopsis of continuous assessment from 1994 to 2005. Antimicrob Agents Chemother 52 : 288–298. [Google Scholar]
  6. Carme B, 2005. Substantial increase of malaria in inland areas of eastern French Guiana. Trop Med Int Health 10 : 154–159. [Google Scholar]
  7. Picot S, 2006. Is Plasmodium vivax still a paradigm for uncomplicated malaria? Med Mal Infect 36 : 406–413. [Google Scholar]
  8. D’Ortenzio E, Durand R, Pradines B, Parzy D, Lebras J, 2005. Dernières recommandations sur la prévention et le traitement du paludisme. Available at: http://www.phans.asso.fr/Documents%20partages/Journees%20medicales/PALUDISMEpc.pdf. Accessed January 13, 2009.
  9. Cortese JF, Caraballo A, Contreras CE, Plowe CV, 2002. Origin and dissemination of Plasmodium falciparum drug-resistance mutations in South America. J Infect Dis 186 : 999–1006. [Google Scholar]
  10. Alecrim WD, Dourado H, Alecrim MG, Passos LF, Wanssa E, Albuquerque B, 1982. In vivo resistance of Plasmodium falciparum to the combination of sulfadoxine and pyrimethamine, at RIII level, in Amazonas, Brazil. Rev Inst Med Trop Sao Paulo 24 : 52–53. [Google Scholar]
  11. Espinal CA, Cortes GT, Guerra P, Arias AE, 1985. Sensitivity of Plasmodium falciparum to antimalarial drugs in Colombia. Am J Trop Med Hyg 34 : 675–680. [Google Scholar]
  12. Roper MH, Torres RS, Goicochea CG, Andersen EM, Guarda JS, Calampa C, Hightower AW, Magill AJ, 2000. The epidemiology of malaria in an epidemic area of the Peruvian Amazon. Am J Trop Med Hyg 62 : 247–256. [Google Scholar]
  13. Prajapati SK, Joshi H, Valecha N, Reetha AM, Eapen A, Kumar A, Das MK, Yadav RS, Rizvi MA, Dash AP, 2007. Allelic polymorphism in the Plasmodium vivax dihydrofolate reductase gene among Indian field isolates. Clin Microbiol Infect 13 : 331–334. [Google Scholar]
  14. Alam MT, Bora H, Bharti PK, Saifi MA, Das MK, Dev V, Kumar A, Singh N, Dash AP, Das B, Wajihullah, Sharma YD, 2007. Similar trends of pyrimethamine resistance-associated mutations in Plasmodium vivax and P. falciparum. Antimicrob Agents Chemother 51 : 857–863. [Google Scholar]
  15. Hawkins VN, Joshi H, Rungsihirunrat K, Na-Bangchang K, Sibley CH, 2007. Antifolates can have a role in the treatment of Plasmodium vivax. Trends Parasitol 23 : 213–222. [Google Scholar]
  16. Legrand E, Volney B, Lavergne A, Tournegros C, Florent L, Accrombessi D, Guillotte M, Mercereau-Puijalon O, Esterre P, 2005. Molecular analysis of two local falciparum malaria outbreaks on the French Guiana coast confirms the msp1 B-K1/varD genotype association with severe malaria. Malar J 4 : 26. [Google Scholar]
  17. Snounou G, 1996. Detection and identification of the four malaria parasite species infecting humans by PCR amplification. Methods Mol Biol 50 : 263–291. [Google Scholar]
  18. Imwong M, Pukrittayakamee S, Renia L, Letourneur F, Charlieu JP, Leartsakulpanich U, Looareesuwan S, White NJ, Snounou G, 2003. Novel point mutations in the dihydrofolate reductase gene of Plasmodium vivax: evidence for sequential selection by drug pressure. Antimicrob Agents Chemother 47 : 1514–1521. [Google Scholar]
  19. Korsinczky M, Fischer K, Chen N, Baker J, Rieckmann K, Cheng Q, 2004. Sulfadoxine resistance in Plasmodium vivax is associated with a specific amino acid in dihydropteroate synthase at the putative sulfadoxine-binding site. Antimicrob Agents Chemother 48 : 2214–2222. [Google Scholar]
  20. Hall TA, 1999. BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. Nucleic Acids Symp Ser 41 : 95–98. [Google Scholar]
  21. Targett GAT, 1992. Malaria—drug-use and the immune-response. Parasitology 105 : S61–S70. [Google Scholar]
  22. Tjitra E, Baker J, Suprianto S, Cheng Q, Anstey NM, 2002. Therapeutic efficacies of artesunate-sulfadoxine-pyrimethamine and chloroquine-sulfadoxine-pyrimethamine in vivax malaria pilot studies: relationship to Plasmodium vivax dhfr mutations. Antimicrob Agents Chemother 46 : 3947–5393. [Google Scholar]
  23. Hawkins VN, Auliff A, Prajapati SK, Rungsihirunrat K, Hapuarachchi HC, Maestre A, O’Neil MT, Cheng Q, Joshi H, Na-Bangchang K, Sibley CH, 2008. Multiple origins of resistance-conferring mutations in Plasmodium vivax dihydrofolate reductase. Malar J 7 : 72. [Google Scholar]
  24. McCollum AM, Mueller K, Villegas L, Udhayakumar V, Escalante AA, 2007. Common origin and fixation of Plasmodium falciparum dhfr and dhps mutations associated with sulfadoxine-pyrimethamine resistance in a low-transmission area in South America. Antimicrob Agents Chemother 51 : 2085–2091. [Google Scholar]
  25. Khalil I, Ronn AM, Alifrangis M, Gabar HA, Satti GM, Bygbjerg IC, 2003. Dihydrofolate reductase and dihydropteroate synthase genotypes associated with in vitro resistance of Plasmodium falciparum to pyrimethamine, trimethoprim, sulfadoxine, and sulfamethoxazole. Am J Trop Med Hyg 68 : 586–589. [Google Scholar]

Data & Media loading...

  • Received : 03 Nov 2008
  • Accepted : 26 Feb 2009

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error